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Abstract
Background: Patients with end stage renal disease (ESRD), including stage 5 chronic kidney disease (CKD),
hemodialysis (HD) and peritoneal dialysis (PD), are at high risk for stroke-related morbidity, mortality and bleeding.
The overall risk/benefit balance of warfarin treatment among patients with ESRD and AF remains unclear.
Methods: We systematically reviewed the associations of warfarin use and stroke outcome, bleeding outcome or
mortality in patients with ESRD and AF. We conducted a comprehensive literature search in Feb 2016 using key
words related to ESRD, AF and warfarin in PubMed, Embase and Cochrane Library without language restriction. We
searched for randomized trials and observational studies that compared the use of warfarin with no treatment,
aspirin or direct oral anticoagulants (DOACs), and reported quantitative risk estimates on these outcomes. Paired
reviewers screened articles, collected data and performed qualitative assessment using the Cochrane Risk of Bias
Assessment Tool for Non-randomized Studies of Interventions. We conducted meta-analyses using the random-effects
model with the DerSimonian - Laird estimator and the Knapp-Hartung methods as appropriate.
Results: We identified 2709 references and included 20 observational cohort studies that examined stroke outcome,
bleeding outcome and mortality associated with warfarin use in 56,146 patients with ESRD and AF. The pooled estimates
from meta-analysis for the stroke outcome suggested that warfarin use was not associated with all-cause
stroke (HR = 0.92, 95 % CI 0.74–1.16) or any stroke (HR = 1.01, 95 % CI 0.81–1.26), or ischemic stroke (HR = 0.80,
95 % CI 0.58–1.11) among patients with ESRD and AF. In contrast, warfarin use was associated with
significantly increased risk of all-cause bleeding (HR = 1.21, 95 % CI 1.01–1.44), but not associated with major
bleeding (HR = 1.18, 95 % CI 0.82–1.69) or gastrointestinal bleeding (HR = 1.19, 95 % CI 0.81–1.76) or any
bleeding (HR = 1.21, 95 % CI 0.99–1.48). There was insufficient evidence to evaluate the association between
warfarin use and mortality in this population (pooled risk estimate not calculated due to high heterogeneity).
Results on DOACs were inconclusive due to limited relevant studies.
Conclusions: Given the absence of efficacy and an increased bleeding risk, these findings call into question
the use of warfarin for AF treatment among patients with ESRD.
Keywords: End stage renal disease, Atrial fibrillation, Anticoagulants, Warfarin
* Correspondence: mara@jhu.edu
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public
Health, 615 N. Wolfe St, Baltimore, MD 21205, USA
2Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tan et al. BMC Nephrology  (2016) 17:157 
DOI 10.1186/s12882-016-0368-6
Background
The prevalence of atrial fibrillation (AF) in adults with
end stage renal disease (ESRD) is 11.6 % [1], about
11-times higher than the prevalence of AF in the general
adult population [2]. Among patients with ESRD and AF,
the incidence of stroke is 5.2 per 100 person-years and the
incidence of mortality is 26.9 per 100 person-years. These
incidences are notably higher than the incidence of stroke
(1.9 per 100 person-years) and the incidence of mortality
(13.4 per 100 person-years) in patients with ESRD who do
not have AF [1].
Anticoagulation therapy, such as warfarin, is commonly
prescribed to prevent ischemic stroke and its efficacy is
well demonstrated in a meta-analysis of randomized trials
and observational studies in patients with chronic kidney
disease (CKD) and AF [3]. Another meta-analysis sug-
gested that using warfarin does not significantly increase
adverse bleeding outcomes among patients with AF and
mild to moderate CKD [4]. Direct oral anticoagulants
(DOACs) including dabigatran, rivaroxaban and apixaban
are available as alternatives to warfarin therapy for preven-
tion of stroke and systemic thromboembolism in patients
with AF without renal impairment. Some data on DOACs
suggested a higher efficacy [3] and lower bleeding risk [4]
of these agents compared with warfarin in patients with
CKD and AF. However, the product labels stated that the
use of dabigatran and rivaroxaban should be avoided in
patients with severe renal impairment (i.e. creatinine
clearance [CrCl] < 30 mL/min). Previous randomized con-
trolled trials have excluded patients with advanced CKD
on dialysis and thus there remains a lack of evidence to
support the use of warfarin or DOACs in this population.
Despite the wealth of evidence of anticoagulation therapy
in patients with CKD, the benefits and risks of warfarin
and DOACs in patients with ESRD and AF are unclear.
The guidelines for warfarin treatment in patients with
ESRD and AF are not uniform. The current American
Heart Association/American College of Cardiology/
Heart Rhythm Society (AHA/ACC/HRS) guideline rec-
ommends warfarin for oral anticoagulation in patients
with ESRD and nonvalvular AF who have a CHA2DS2-
VASc score of 2 or greater [5]. The Kidney Disease Im-
proving Global Outcomes (KDIGO) guideline suggests
that routine anticoagulation in patients with ESRD and
AF for primary prevention of stroke is not indicated
because of increased risk for bleeding and lack of sys-
tematic evidence for stroke prevention benefit, whereas
recommendations for secondary prevention and careful
monitoring of all patients receiving dialysis anticoagula-
tion remain valid [6]. Recently published systematic
reviews which examined the benefit and risk of warfarin
in patients with ESRD and AF were limited to patients
on hemodialysis (HD) or peritoneal dialysis (PD) [7, 8],
or used an inappropriate measure of association (risk
ratio [RR] instead of hazard ratio [HR]) [9]. Because the
risk of outcomes may not remain constant over the
study period and loss to follow up are common in obser-
vational studies, HR is more appropriate for evaluating
the effects of warfarin as most observational studies
report time-to-event data. Moreover, these studies
reported conflicting results regarding the association be-
tween warfarin use and stroke outcome: one review re-
ported warfarin use was associated with higher risk of
any stroke (RR 1.50, 95 % CI: 1.13–1.99) [9] while other
reviews reported a lack of association between warfarin
use and stroke [7, 8, 10].
Therefore, we expanded the population to stage 5 CKD,
HD, and PD and conducted a systematic review and
meta-analyses on the benefits and risks of warfarin use.
We used appropriate analytic tools such as the Cochrane
Risk of Bias Assessment Tool for Non-randomized Studies
of Interventions [11] for qualitative assessment and the
Knapp-Hartung methods [12] for quantitative assessment.
The objective of this study was to review and summarize
the associations between warfarin use and stroke out-
comes, bleeding outcomes and all-cause mortality, as
compared to no warfarin use, aspirin or DOACs, among
patients with ESRD and AF.
Methods
Search strategy
We performed the systematic review and meta-analysis in
adherence to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. First,
we searched PubMed, Embase and the Cochrane Central
register using synonyms and variations of the following
search terms without language or date restrictions: “end
stage renal disease”, and “atrial fibrillation” and “anticoag-
ulants or warfarin”. We used a combination of controlled
vocabulary (e.g. MeSH and Emtree), free-text words (i.e.
words appearing in the title, abstract or keywords of a
database entry), and truncated terms as appropriate for
each database (Appendix). All databases were searched
from their start date to February 10, 2016. In addition to
the electronic database searches, we hand-searched the
reference lists of review articles, relevant studies and
clinical practice guidelines.
Study selection
We searched for published randomized controlled trials
(RCTs) and quasi-RCTs (RCTs in which allocation to
treatment was obtained by alternation, use of alternate
medical records, date of birth or other predictable
methods), and observational studies which examined the
benefits and risks of warfarin in patients with ESRD and
AF. We included studies of at least 10 patients with
ESRD (HD, PD, stage 5 CKD i.e. GFR < 15 mL/min/
1.73 m2) and with pre-existing or newly diagnosed AF
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(all types). We also included studies with broader study
populations (i.e. CKD) if they reported outcomes separately
for participants with ESRD. We included studies which
compared warfarin use with placebo, no treatment or other
antithrombotic agents (e.g. aspirin, dabigatran, rivaroxban,
apixaban). Studies needed to report quantitative data on
the risk for any of the following outcomes: all-cause stroke
(any stroke i.e. including ischemic stroke, hemorrhagic
stroke, systematic thromboembolism and transient ische-
mic attacks; ischemic stroke), all-cause bleeding (any bleed-
ing, major bleeding, gastrointestinal bleeding) or all-cause
mortality. We only reviewed full articles because conference
abstracts would not provide the details necessary for quali-
tative and quantitative assessments.
Data collection
Two reviewer authors (JT, SL) independently conducted
abstract screening and selected relevant studies for data
abstraction according to the inclusion/exclusion criteria
above. We used a web-based systematic review software
DistillerSR (Evidence Partners, Ottawa, Canada) to
document the article screening process and to develop
standardized data collection forms. For each study, we
abstracted bibliographic information (first author, publi-
cation year); general information (location of study,
sample size, number of treatment groups, number of
participants); participant characteristics (age, gender,
history of stroke and bleeding); interventions (treatment
groups); outcomes (definition, analytic method, crude
event data, adjusted risk estimates (HR) and their 95 %
CIs); and study quality. We also contacted the corre-
sponding authors of four included studies [13–16] to
obtain missing outcome data. We used the Cochrane
Risk of Bias Assessment Tool for Non-Randomized
Studies of Interventions (ACROBAT-NRSI) [11] to assess
the risk of bias because it was designed specifically for
non-randomized studies that evaluate effectiveness of
interventions. We rated the risk of bias on seven domains
at the study level, and rated the overall risk of bias based
on the domain with the highest risk of bias. Discrepancies
in study selection and data collection were resolved by the
two reviewers through discussions and consensus.
Data analysis
We assessed the clinical and methodologic heterogeneity
in participant characteristics (i.e. ESRD status, age, gender,
comorbidities, prevalent vs. incident warfarin users) and
assessments of outcomes (i.e. outcome definitions and
analytic methods). We used the Cochran Q test, which
follows a Chi-square distribution with n-1 of freedom,
with an alpha of < 0.10 to assess the presence of statistical
heterogeneity between studies. We also calculated the I2
statistic, which ranges between 0 and 100 %, to determine
the proportion of between group variability that is
attributable to heterogeneity rather than chance [17]. If
there was evidence for considerable heterogeneity (i.e.
I2 ≥ 80 %), we displayed the risk estimates in a forest plot
but did not calculate the overall risk estimates. Otherwise,
we conducted meta-analyses using the random effects
model with the DerSimonian-Laird estimator [18] and the
Knapp-Hartung approach [12], where appropriate, using
Stata 14.0 (StataCorp, College Station, TX).
Sensitivity analysis
We performed pre-specified sensitivity analyses where
studies with prevalent warfarin users and studies with
low methodological quality were excluded from meta-
analyses. We assessed the presence of publication bias
using funnel plots with the natural log of HR plotted on
the y-axis and the standard error of natural log of HR
plotted on the x-axis. We also tested the presence of
small-study effects using the Egger’s test [19]. We con-
ducted meta-regressions with the Knapp-Hartung approach
to evaluate the impact of study quality (moderate/high risk
of bias vs critical risk of bias), patient population (HD only
vs mixed ESRD population), and study design (studies
including incident warfarin users only vs. studies including
prevalent and incident warfarin users) on stroke outcome,
bleeding outcome or mortality.
Results
Description of included studies
We identified 2709 references from the electronic data-
base search; no additional references were identified from
hand searching. After removing 593 duplicate references
and excluding 2022 references in titles and abstracts
screening, we did a full-text review of 94 references. After
excluding another 74 references, we included 20 articles
for qualitative and quantitative assessment (Fig. 1).
All 20 investigations were observational cohort studies
examining the outcomes of warfarin use in patients with
ESRD and AF. Nineteen studies compared warfarin use
to no warfarin use, while two studies also compared
warfarin use to aspirin [20, 21] and one study compared
warfarin use to dabigatran and rivaroxaban [20]. A total
of 56,146 patients with ESRD and AF, including 34,840
on HD, 315 on PD, 610 with stage 5 CKD, and 20,381
mixed ESRD population, were included in these studies.
These studies included a median of 690 (interquartile
range [IQR] 204–3012) patients with ESRD and AF, and
had a median duration of 7.0 (IQR 2.9–9.4) years. Eight
studies were based on administrative claims or national/
regional registry data [13, 22–28], and they generally
were longer and larger studies. Twenty studies included
participants with a mean age above 60 years old, including
two studies that were limited to older adults above 65 years
old [22, 27]. Nine studies examined effects of warfarin use
between incident warfarin users and nonusers [20, 22–29],
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whereas the other 11 studies compared prevalent warfarin
users with nonusers (Table 1, Appendix Table 3).
Risk of bias assessment
Due to the observational nature of cohort studies, all 20 in-
cluded studies had at least an overall rating of moderate
risk of bias: 5 studies were rated as moderate [22, 25–28]; 7
studies were rated as serious [13, 14, 20, 23, 24, 30, 31]; 8
studies were rated as having a critical risk of bias [14–16,
21, 29, 32–35] (Table 2, Appendix Table 4).
Association of warfarin with stroke, bleeding and
mortality
The meta-analyses of warfarin use included 15 studies
that examined all-cause stroke (I2 68.1 %), 11 studies
that examined all-cause bleeding (I2 48.3 %), and 12
studies that examined all-cause mortality (I2 85.7 %) and
reported HRs as outcome measures (Fig. 2a-c). Warfarin
use was not statistically associated with reduction in all-
cause stroke (HR 0.92, 95 % confidence interval [CI]
0.74–1.16) (Fig. 2a), and was not associated with any
stroke (HR 1.01, 95 % CI 0.81–1.26) or ischemic stroke
(HR 0.80, 95 % CI 0.58–1.11).
By contrast, there was a positive and statistically
significant association between warfarin use and all-
cause bleeding (HR 1.21, 95 % CI 1.01–1.44) (Fig. 2b).
Warfarin use was not associated with major bleeding
(HR 1.18, 95 % CI 0.82–1.69) or gastrointestinal
bleeding (HR 1.19, 95 % CI 0.81–1.76). While there
was a trend towards increased risk of any bleeding,
the association was not significant (HR 1.21, 95 % CI
0.99–1.48).
Finally, there was high statistical heterogeneity among
the 12 studies (I2 = 85.7 %) that examined all-cause mor-
tality, and thus we did not calculate an overall risk esti-
mate (Fig. 2c). Most studies showed non-significant
results except for 4 studies that found lower risk of mor-
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Fig. 1 PRISMA flow diagram of study selection for systematic review
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Table 1 Characteristics of warfarin studies in patients with end stage renal disease and atrial fibrillation
Author Year Setting Study duration
(years)
Study population Study groups Number of patients
with ESRD and AF








US, Fresenius clinics 1.6 Patients with incident HD, pre-existing AF T (total) 1671 NR NR NR NR
W (warfarin) 746 NR NR NR NR
C (no warfarin) 925 NR NR NR NR
Lai 2009 [32] US, single center 2.6 All patients with CKD (HD and GFR
< 15 mL/min/1.73 m2) and pre-existing
non-valvular AF, includes prevalent
warfarin users
T (total) 245 NR NR NR NR
W (warfarin) 129 NR NR NR NR





8 Patients with HD who had pre-existing or
newly developed AF, includes prevalent
warfarin users
T (total) 3245 NR NR NR NR
W (warfarin) 509 NR NR NR NR






22 All patients with incident dialysis ≥ 66 years
who had first hospitalization with a primary
or secondary discharge diagnosis of AF
T (total) 2313 NR NR NR NR
W (warfarin) 249 57.4 68.6 (12.1) NR 6.8





12 All patients discharged from the hospital
with a diagnosis of non-valvular AF,
receiving RRT
T (total) 901 33.6 66.8 (11.7) 14.8 15.2
W (warfarin only) 178 NR NR NR NR
C (no warfarin) 723 NR NR NR NR
Khalid
2013 [34]
US, multi-center 6 Patients who were started on warfarin in
the last year and re-started warfarin for
atrial fibrillation after a gastrointestinal bleed
T (total) 96 31.3 77.2 (10.6) 52.1 21.2
W (restarted warfarin) 34 NR NR NR NR
C (did not restart warfarin) 62 NR NR NR NR
Wakasugi
2014 [29]
Japan, multi-center 3 Patients aged ≥ 20 years with ESRD
requiring HD and pre-existing chronic
sustained AF, includes prevalent
warfarin users
T (total) 60 NR NR NR NR
W (warfarin) 28 43 67.8 (9.4) 14 NR





15 Incident non-valvular AF discharge,
receiving RRT, stratified by CHA2DS2-
VASc score
T (total) 1142 35.03 66.77
(12.03)
16.37 17.51
W (warfarin) 260 NR NR NR NR





7 Survivors of acute myocardial infarction,
history of AF or AF diagnosis in hospital,
eGFR ≤ 15 ml/min/173 m2
T (total) 478 NR NR NR NR
W (warfarin) 66 37.9a 78a (NR) 28.8a 12.1a





4.12 Adult (≥18 years) patients with ESRD,
receiving RRT, pre-existing non-valvular AF
T (total) 3277 NR NR NR NR
W (warfarin) 294 58.5 NR NR NR
C (no warfarin) 2983 53.7 NR NR NR
Friberg
2014 [13]
Sweden, national registry 2.1 Any inpatient diagnosis of non-valvular AF,
receiving RRT, includes prevalent
warfarin users
T (total) 13435 35.7 78.4 (10.3) 24.6 30.5
W (warfarin) 3766 NR NR NR NR

















9 Patients aged ≥ 65 years admitted to a
hospital with a primary or secondary
diagnosis of AF who underwent > = 3
dialysis procedure within the 12 months
preceding AF
T (total) 1626 NR NR NR NR
W (warfarin) 756 39 75.3 (8.1) 6 9
C (no warfarin) 870 39 75.1 (8.5) 5 16
Genovesi
2015 [31]
Italy, multi-center 2 Patients with HD, pre-existing paroxysmal,
persistent or permanent AF, includes
prevalent warfarin users
T (total) 290 40.0 NR 14.8 19.7
W (warfarin) 134 35.8 NR 15.7 11.9
C (no warfarin) 156 43.6 NR 14.1 26.3
Chan KE
2015 [20]
US, Fresenius clinics 4 Patients with chronic HD, pre-existing AF T (total) 14607 NR NR NR NR
W (warfarin) 8064 38.8 70.6 (11) 12.7 3.3
A (aspirin) 6018 42.7 71.7 (11) 14.3 0.7
D (dabigatran) 281 40.8 68.4 (12) 12.5 4.1
R (rivaroxaban) 244 39.5 66.9 (12) 16.0 4.2
Chan PH
2015 [21]
China, single center 14.5 Patients with PD who had a diagnosis of
AF treated in two hospitals, exclude HD
or CKD stage 5 not on RRT, includes
prevalent warfarin users
T (total) 271 NR NR NR NR
W (warfarin) 67 41.8 69.5 (9.5) 17.9 1.5
A (aspirin) 86 41.9 73.0 (10.0) 25.6 4.7
C (no antithrombotic
therapy)





4 All patients with HD who had a new
diagnosis of AF based on 1 inpatient or
2 outpatient diagnosis codes
T (total) 12284 NR NR NR NR
W (warfarin) 1838 50.3 61.2 (12.4) NR NR





9 Patients with ESRD commenced on
long-term dialysis at a hospital who had
pre-existing or developed AF, includes
prevalent warfarin users
T (total) 141 38.3 61.2 (11.3) NR 19.1
W (warfarin) 59 39.0 59.8 (10.5) NR 16.9
C (no warfarin) 82 37.8 62.1 (11.8) NR 20.7
Yodogawa
2015 [35]
Japan, single center 9.5 Patients aged ≥ 20 years with AF and ESRD
requiring maintenance HD, includes
prevalent warfarin users
T (total) 84 30 NR 5 6
W (warfarin) 30 20 69.5 (10.7) 10 3
C (no warfarin) 54 35 70.4 (10.2) 2 7
Findlay
2016 [15]
UK, single center 7 Adult patients receiving hemodialysis,
exclude those treated for acute kidney
injury, includes prevalent warfarin users
T (total) 293 NR NR NR NR
W (warfarin) 118 NR NR NR NR
C (no warfarin) 175 NR NR NR NR
Tanaka
2016 [16]
Japan, multi-center 2.5 Patients with ESRD with dialysis initiation
who became stable and were discharged
from hospital with or without AF, includes
prevalent warfarin users
T (total) 93 37.6 NR NR NR
W (warfarin) 46 26.1 73.6 (8.5) 19.6 6.5
C (no warfarin) 47 34.0 70.7 (12.1) 8.5 0.0
AF atrial fibrillation, HD hemodialysis, PD peritoneal dialysis, CKD chronic kidney disease, ESRD end stage renal disease, RRT renal replacement therapy, NR not reported
A all relevant patients with ESRD and AF included in study, T patients with ESRD and AF in the treatment group, C patients with ESRD and AF in the comparison group































Chan 2009 [30] Serious Moderate Serious Low Low Low Low Moderate
Lai 2009 [32] Critical Critical Serious Serious Serious No info Low Moderate
Wizemann 2010 [33] Critical Serious Critical Moderate No info No info Moderate Serious
Winkelmayer 2011 [22] Moderate Moderate Low Low Low Low Low Moderate
Olesen 2012 [23] Serious Serious Low Low Serious Low Low Moderate
Khalid 2013 [34] Critical Critical Critical Moderate Serious No info Low Moderate
Wakasugi 2014 [29] Critical Critical Serious Low Low No info Low Moderate
Bonde 2014 [24] Serious Serious Low Moderate Serious Low Low Serious
Carrero 2014 [25] Moderate Moderate Low Low Low Low Low Moderate
Chen 2014 [26] Moderate Moderate Low Low Low Low Low Moderate
Friberg 2014 [13] Serious Moderate Serious Low Low Low Low Moderate
Shah 2014 [27] Moderate Moderate Low Low Low Low Low Moderate
Genovesi 2015 [31] Serious Moderate Serious Low Low No info Low Moderate
Chan KE 2015 [20] Serious Moderate Low Low Serious Low Low Moderate
Chan PH 2015 [21] Critical Serious Critical Low Serious Low Moderate Moderate
Shen 2015 [28] Moderate Moderate Low Low Low Low Low Moderate
Wang 2015 [14] Critical Serious Critical Low Serious No info Moderate Serious
Yodogawa 2015 [35] Critical Serious Critical Moderate No info Low Moderate Moderate
Findlay 2016 [15] Critical Critical Critical No info Critical No info Moderate Moderate













In the sensitivity analysis in which we excluded 11 stud-
ies with prevalent warfarin users, the overall risk esti-
mates were 0.88 (95 % CI 0.65–1.18) for all-cause stroke,
1.14 (95 % CI 0.88–1.47) for all-cause bleeding, and 0.99
(95 % CI 0.83–1.17) for mortality respectively (Appendix
Figure 4a–c). In the analysis which we included only
studies with prevalent users, the results were consistent
with the aforementioned sensitivity analysis: the overall
risk estimates were 0.99 (95 % CI 0.69–1.42) for all--
cause stroke, 1.31 (95 % CI 0.91–1.87) for all-cause
bleeding, 0.72 (HR 0.47–1.11) for all-cause mortality. In
the sensitivity analysis in which we excluded studies
with critical risk of bias and low methodological qual-
ity (Appendix Figure 5a–c), the results were not sta-
tistically significant (all-cause stroke: HR 0.91, 95 %
CI 0.73–1.14; all-cause bleeding: HR 1.13, 95 % CI
0.99–1.28; pooled risk estimate for mortality not cal-
culated due to heterogeneity).
In the meta-regression, we did not find significant im-
pact of study characteristics on outcomes except for
study population in the analysis of all-cause stroke out-
come. Compared to studies that included mixed ESRD
population, studies including only patients on HD re-
ported higher association with all-cause stroke outcome
(OR 5.83, 95 % CI 1.22–27.98; P = 0.03). In the funnel
plots, we did not observe obvious asymmetry in the fun-
nel plots for all three outcomes (Fig. 3a–c). Statistical
tests for small-study effects were not statistically signifi-
cant for the three outcomes (P = 0.21, 0.51 and 0.68 for
all-cause stroke, all-cause bleeding and all-cause mortal-
ity respectively).
Fig. 2 a Meta-analysis of stroke outcome in patients with end stage renal disease and atrial fibrillation by warfarin use. b Meta-analysis of bleeding
outcome in patients with end stage renal disease and atrial fibrillation by warfarin use. c Forest plot of mortality in patients with end stage renal
disease and atrial fibrillation by warfarin use
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Discussion
We conducted a systematic review and meta-analyses of
20 observational studies examining the benefits and risks
of warfarin use among patients with ESRD and AF. Meta-
analyses provided no evidence to suggest associations be-
tween warfarin use and all-cause stroke (HR 0.92, 95 % CI
0.74–1.16) among these patients. By contrast, warfarin use
was associated with a significantly increased risk of all-
cause bleeding (HR 1.21, 95 % CI 1.01–1.44). There were
insufficient data with good quality to estimate the associ-
ation between warfarin use and mortality.
We did not evaluate hemorrhagic stroke in the meta-
analyses because only two studies reported hemorrhagic
stroke as separate outcomes (Appendix Table 4) [22, 30].
Chan et al. reported that warfarin use was significantly
associated with increased risk of hemorrhagic stroke
(HR 2.22, 95 % CI 1.01–4.91) [30], and Winkelmayer et
al. also reported that warfarin use was associated with
hemorrhagic stroke (HR 2.38, 95 % CI 1.15–4.96) [22].
We attempted to evaluate warfarin use vs aspirin or
DOACs which was not examined in previously published
systematic reviews and meta-analyses, but there were
not enough studies to draw conclusions regarding these
comparisons. For the two studies that examined
ischemic stroke outcomes comparing warfarin vs aspirin,
one study showed significant increased risk from war-
farin (unadjusted rate ratio (RR) 1.23, 95 % CI 1.01–
1.52) [20] whereas another study showed a significant
reduced risk (adjusted HR: 0.16, 95 % CI 0.04–0.66) [21].
Warfarin was associated with significantly increased risk
of major bleeding compared to aspirin (adjusted RR
1.28, 95 % CI 1.19–1.39) [20]. On the other hand, dabi-
gatran (RR 1.48, 95 % CI 1.21–1.81) and rivaroxaban
(RR 1.38, 95 % CI 1.02–1.83) were associated with higher
risk of hospitalization or death from bleeding when
compared with warfarin [20]. In terms of stroke, the au-
thors noted that there were too few events in the study
to detect meaningful differences.
Compared to previously published systematic reviews
[7–10], our review included several studies recently pub-
lished [15, 16, 35] and expanded the study population to
include PD [21] and stage 5 CKD [25], which were not
included in these reviews [7–9, 36]. Our pooled estimate
of ischemic stroke and bleeding outcomes were consist-
ent in direction and magnitude with those reported by
Li et al., Liu et al. and Dahal et al. [7, 8, 10]. On the
other hand, Lee et al. found that warfarin use was associ-
ated with increased risk of any stroke (RR 1.50, 95 % CI
Fig. 3 a Funnel plot of stroke outcome in patients with end stage renal disease and atrial fibrillation. b Funnel plot of bleeding outcome in
patients with end stage renal disease and atrial fibrillation. c Funnel plot of mortality in patients with end stage renal disease and atrial fibrillation
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1.13–1.99) [9], but our result was not significant (HR
1.01, 95 % CI 0.81–1.26) because we included eight more
studies in our meta-analysis [13–15, 23, 26, 28, 31, 35]
and abstracted a less extreme risk estimate from one of
the studies [9, 30]. We would like to point out that we
abstracted the results from the intention-to-treat ana-
lysis from Shen et al. for the meta-analyses [28], whereas
other systematic review abstracted the results from the
as-treated analysis from Shen et al. [8]. Such difference
did not change the general inferences about the lack of
association between warfarin use and stroke and the in-
creased risk of bleeding outcome.
Warfarin acts by inhibiting the synthesis of vitamin
K-dependent clotting factors, and its anticoagulation ef-
fect is influenced by possible interactions between drugs
or foods and warfarin [37]. The effectiveness of warfarin
use for stroke prevention is crucially dependent on the
quality of anticoagulation therapy, which can be moni-
tored by international normalized ratio (INR) and time
in therapeutic range (TTR). Only 5 of the included stud-
ies discussed the influence of INR or TTR on the out-
come results [13, 20, 30–32]. Patients with suboptimal
warfarin management (e.g. warfarin users who did not
receive INR monitoring [30] or patients with TTR < 60 %
[13]) have the highest risk for stroke and thromboembol-
ism. Increasing baseline INR level in warfarin users was
positively associated with new stroke [30]. On the other
hand, patients with CKD and AF treated with warfarin to
maintain an INR between 2.0 and 3.0 had a significant
reduction in thromboembolic stroke [32]. Higher TTR, an
indicator for good warfarin management, had protect-
ive effect against bleeding risk [31]. These results
highlighted the difficulty in achieving optimal warfarin
management in patients with ESRD and AF, which
could help explain the heterogeneous outcomes of
warfarin use in this population.
Our review has several strengths including our con-
duct of a comprehensive search in multiple electronic
databases with the application of rigorous qualitative
and quantitative assessment. We performed our qualita-
tive assessment using the recently developed Cochrane
Risk of Bias Assessment Tool for Non-Randomized
Studies of Interventions, which was designed specifically
for non-randomized studies that compare the health
effects of two or more intervention [11], and unlike the
Newcastle-Ottawa scale, does not require modification
for use in reviews of effectiveness of interventions [38].
We conducted our quantitative assessment using the
Knapp-Hartung method based on small-sample adjust-
ments [12], which provided more accurate confidence
limits than the DerSimonian-Laird estimator and has
been advocated as an alternative method for meta-
analysis with a limited number of studies [39, 40]. In
addition, we were able to obtain missing outcome data
from four study authors [13–16], and thus examined a
greater number of studies than previous authors.
Our report also has several limitations. First, we
observed high heterogeneity (I2 = 85.7 %) in all-cause
mortality across the 12 studies [13–16, 22, 24, 25, 28–
30, 34], which limited our ability to estimate a pooled
risk estimate. In the sensitivity meta-analysis of all-cause
mortality using studies that only included incident war-
farin users [22, 24, 25, 28], the pooled risk estimate was
not statistically significant (HR 0.99, 95 % CI 0.79–1.22).
Second, we were not able to conduct meta-analysis on
the association between warfarin use and hemorrhagic
stroke or on the comparison between warfarin and
aspirin or DOACs because there were insufficient stud-
ies available on this topic. Finally, as with all systematic
review and meta-analyses, our results were limited by
the quality of the available studies for inclusion.
Although all included studies reported warfarin use in
patients with ESRD and AF, we could not confirm that
such use was indicated for AF treatment because the
included studies did not report such information. We
could not verify that the ischemic outcomes reported in
the included studies were confirmed by imaging, since
several studies were based on administrative claims or
registry data [13, 22, 27, 28].
We observed substantial clinical and methodological
heterogeneity in the studies we examined with respect to
participant characteristics, study conduct and outcome
assessment. Study population seems to have significant
impact on the association between warfarin use and all--
cause stroke outcome as evidenced in the meta-
regression. Compared to 9 studies that included patients
on HD only, 6 studies that included mixed ESRD popu-
lation [13, 14, 22, 23, 26] or patients on PD only [41]
reported lower association between warfarin use and all-
cause stroke. This may reflect heterogeneous treatment
effects among subgroups of patients with ESRD and
requires further investigation. Although meta-regression
did not show significant impact on outcomes due to
study quality or study design, these characteristics
helped explain the heterogeneity observed in the in-
cluded studies. A majority of the included studies had
serious or critical risk of bias, particularly in the bias
due to confounding [14–16, 21, 23, 24, 29, 32–35], bias
in selection of participants [13, 20, 29, 31–34], and bias
due to departures from intended interventions domains
[13, 15, 16, 20, 21, 23, 24, 31, 32, 34, 42]. While all stud-
ies attempted to control for confounding bias by covari-
ate adjustment or propensity score adjustment/matching
except for one [15], there may be inherent confounding
bias due to unobserved covariates, residual confounding
or unsuccessful adjustment. Studies that included preva-
lent [13, 15, 16, 21, 29, 31–35, 42], rather than new war-
farin users, could introduce selection bias because the
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effect measure was weighted toward prevalent users who
had survived the early events [43]. This would underesti-
mate the events that occur early among prevalent users
when the risk of treatment-related outcome varies with
time [44]. Patients that started on warfarin could discon-
tinue the therapy and thus switched over to the non-use
group, leading to bias due to departures from intended
interventions [28].
Conclusions
Despite the degree of heterogeneity across studies and
the bias in selected studies, our study showed that war-
farin use was not associated with a lower risk of ische-
mic stroke, consistent with recent studies [7–9], and was
associated with a significant higher risk for bleeding [7–
10, 36] among patients undergoing HD. There was in-
sufficient evidence with good quality to estimate the as-
sociation between warfarin use and hemorrhagic stroke
or mortality. Given the limitations of observational stud-
ies described above, large randomized controlled trials
involving patients with ESRD and AF may be warranted
to definitively evaluate the benefits and risks of warfarin.
However, we recognize that such study may be too
costly to be carried out, so high-quality observational
studies are necessary to address the clinical decision di-
lemma regarding warfarin use in this population.
Appendix
Search strategies in PubMed, Embase and Cochrane Library
PubMed
#1 kidney failure, chronic [mh] OR renal insufficiency,
chronic [mh] OR renal replacement therapy [mh] OR
renal dialysis [mh] OR kidney transplantation [mh]
OR kidney disease [tw] OR renal disease [tw] OR kid-
ney failure [tw] OR renal failure [tw] OR kidney dysfunc-
tion [tw] OR renal dysfunction [tw] OR kidney
impairment [tw] OR renal impairment [tw] OR kidney
insufficiency [tw] OR renal insufficiency [tw] OR ESRD
[tw] OR CKD [tw] OR kidney replacement therap* [tw]
OR renal replacement therap* [tw] OR dialy* [tw] OR
hemodialysis [tw] OR haemodialysis [tw] OR hematodia-
lysis [tw] OR kidney transplantation [tw] OR renal trans-
plantation [tw] OR kidney grafting [tw]
#2 atrial fibrillation [mh]
OR atrial fibrillation [tw] OR auricular fibrillation [tw]
OR atrium fibrillation [tw]
#3 anticoagulants [mh] OR warfarin [tw]
OR anticoag* [tw] OR anti-coag* [tw] OR vitamin K
antagonist [tw] OR VKA [tw] OR antithrombo* [tw] OR
anti-thrombo* [tw] OR warfarin [mh] OR indirect
thrombin inhibitor [tw] OR Coumadin* [tw] OR couma-
rin* [tw] OR dabigatran [tw] OR factor Xa inhibitor [tw]
OR rivaroxaban [tw] OR apixaban [tw]
#1 AND #2 AND #3
Embase
#1 ‘end stage renal disease’/exp OR ‘chronic kidney fail-
ure’/exp OR ‘renal replacement therapy’/exp OR ‘kidney
transplantation’/exp
OR ‘kidney disease’:ab,ti OR ‘renal disease’:ab,ti OR
‘kidney failure’:ab,ti OR ‘renal failure’:ab,ti OR ‘kidney
dysfunction’:ab,ti OR ‘renal dysfunction’:ab,ti OR ‘kidney
impairment’:ab,ti OR ‘renal impairment’:ab,ti OR ‘kidney
insufficiency’:ab,ti OR ‘renal insufficiency’:ab,ti OR esr-
d:ab,ti OR ckd:ab,ti OR (‘kidney replacement’ NEXT/1
therap*):ab,ti OR (‘renal replacement’ NEXT/1 thera-
p*):ab,ti OR dialy*:ab,ti OR hemodialysis:ab,ti OR hae-
modialysis:ab,ti OR hematodialysis:ab,ti OR ‘kidney
transplantation’:ab,ti OR ‘renal transplantation’:ab,ti OR
‘kidney grafting’:ab,ti
#2 ‘atrial fibrillation’/exp
OR ‘atrial fibrillation’:ab,ti OR ‘auricular fibrillatio-
n’:ab,ti OR ‘atrium fibrillation’:ab,ti
#3 ‘anticoagulant agent’/exp OR ‘warfarin’/exp OR
anticoag*:ab,ti OR (anti NEXT/1 coag*):ab,ti OR ‘vitamin
k antagonist’:ab,ti OR vka:ab,ti OR antithrombo*:ab,ti
OR (anti NEXT/1 thrombo*):ab,ti OR warfarin:ab,ti OR
‘indirect thrombin inhibitor’:ab,ti OR coumadine:ab,ti
OR dabigatran:ab,ti OR ‘factor xa inhibitor’:ab,ti OR riv-
aroxaban:ab,ti OR apixaban:ab,ti
#1 AND #2 AND #3
Cochrane library
ID Search
#1 MeSH descriptor: [Kidney Failure, Chronic] ex-
plode all trees
#2 MeSH descriptor: [Renal Insufficiency, Chronic]
explode all trees
#3 “kidney disease” or “renal disease” or “kidney fail-
ure” or “renal failure” or “kidney dysfunction” or “renal
dysfunction” or “kidney impairment” or “renal impair-
ment” or “kidney insufficiency” or “renal insufficiency”
or ESRD or CKD
#4 MeSH descriptor: [Renal Replacement Therapy] ex-
plode all trees
#5 MeSH descriptor: [Renal Dialysis] explode all trees
#6 MeSH descriptor: [Kidney Transplantation] explode
all trees
#7 kidney replacement therap* or renal replacement
therap* or dialy* or hemodialysis or haemodialysis or
hematodialysis or “kidney transplantation” or “renal
transplantation” or “kidney grafting”
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Atrial Fibrillation] explode all trees
#10 “atrial fibrillation” or “auricular fibrillation” or
“atrium fibrillation”
#11 #9 or #10
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#12 MeSH descriptor: [Anticoagulants] explode all trees
#13 MeSH descriptor: [Warfarin] explode all trees
#14 anticoag* or anti-coag* or “vitamin K antagonist” or
VKA or antithrombo* or anti-thrombo* or warfarin or
“indirect thrombin inhibitor” or coumadine or dabigatran
or “factor Xa inhibitor” or rivaroxaban or apixaban
#15 #12 or #13 or #14
#16 #8 and #11 and #15
Table 3 Stroke, bleeding and mortality outcomes reported in included studies
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No adjustment Any stroke Clinical diagnosis of
stroke, presence of
ischemic or hemorrhagic


























Adjusted for: age, sex,
ACE/ARB, diabetes,




















AF atrial fibrillation, HD hemodialysis, PD peritoneal dialysis, CKD chronic kidney disease, ESRD end stage renal disease, RRT renal replacement therapy, CI
confidence interval, NR not reported, MF model failed to converge, CAD coronary artery disease, ICH intracranial hemorrhage, GFR glomerular filtration rate, AD
aortic disease
aData were abstracted from online supplement
bReference paper reported cumulative proportion instead of rates
cEffect measures listed in the table were from the ITT analysis or propensity score adjusted/matched analysis
dReference table reported unadjusted HR
eQuality of warfarin treatment (i.e. INR or TTR) information provided
fNumbers were combined from CHA2DS2-VASc score = 0, = 1, and > = 2 subgroups
g Reference paper reported RR instead of HR. Effect measure and 95 % CI was calculated by taking the reciprocal of the reported RR
h Effect measure and/or 95 % CIs were obtained from personal communication with the study author
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Table 4 Risk of bias assessment of included studies
Included Study Judgment Description
Chan 2009 [30]
Bias due to confounding Moderate Analyses were adjusted for risk factors for stroke. These critically important domains were
adjusted for using Cox regression analysis, and confirmed by propensity score adjusted
analysis.
Bias in selection of participants into
the study
Serious Study “excluded patients with <90 d of study enrollment” so there may be some selection
bias. “Patient outcomes were followed from the date of analysis initiation”, and drug
exposure status was determined in the first 90 days of dialysis. Start of follow up and start
of intervention do not coincide for all participants.
Bias in measurement of interventions Low Intervention status well defined and based on information collected at the time of intervention.
Bias due to departures from intended
interventions
Low The primary analysis was intention-to-treat whereby patients were not re-classified, two validation
analyses with censoring and time-varying Cox model were used to account for departures from
intended interventions. “Similar results were noted when patients were censored when they
changed their warfarin, clopidogrel or aspirin prescription after study enrollment.”
Bias due to missing data Low Variables were identified from computerized medical results, so data were reasonably
complete.
Bias in measurement of outcomes Low Outcomes were identified from the diagnoses obtained from hospital discharge summaries
or medical records. The methods of outcome assessment were comparable across
intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
Lai 2009 [32]
Bias due to confounding Critical For the stroke outcome, study did not adjust for congestive heart failure. For the bleeding
outcome, study did not adjust for liver disease, alcohol use and bleeding history. Adjusted
analysis was not applied in comparing incidence of stroke and major bleeding episodes.
Confounding inherently not controllable.
Bias in selection of participants into
the study
Serious All participants who would have been eligible for the target trial were included (“no
patients were excluded from the analysis”). Study included prevalent users, so a potential
important amount of follow-up time is missing for prevalent users from analyses.
Bias in measurement of interventions Serious Intervention status well defined but the intervention status was based on current use vs no
use determined retrospectively. It may be determined in a way that could have been
affected by knowledge of the outcome.
Bias due to departures from intended
interventions
Serious Bias due to departure from the intended intervention is expected, and is not adjusted for
in the analyses.
Bias due to missing data No
information
Medical charts of eligible patients treated in a medical center were reviewed. No information
about loss to follow up or missing data.
Bias in measurement of outcomes Low Outcomes were identified from the medical charts. The methods of outcome assessment were
comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear
indication of selection of the reported analysis from among multiple analyses or
multiple subgroups.
Wizemann 2010 [33]
Bias due to confounding Serious Study adjusted for risk factors in Cox regression analysis, but not confirmed by additional
analyses.
Bias in selection of participants into
the study
Critical Study included patients who had pre-existing (i.e. a history of) AF at enrollment and
patients who subsequently hospitalized with the diagnosis of AF. Study included
prevalent users, so a substantial amount of follow-up time is missing for prevalent
users from analyses.
Bias in measurement of interventions Moderate Intervention is well defined, but some aspects of the assignments of intervention status
were determined retrospectively since self-reported medication use status may be subject
to recall bias.




Study did not describe the analytical method in detail.
Bias due to missing data No
information
Study was based on an international, observational study of HD facilities.
No information about loss to follow up or missing data.
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Table 4 Risk of bias assessment of included studies (Continued)
Bias in measurement of outcomes Moderate Outcomes were identified from hospitalization or death records. The outcome measure
may be minimally influenced by knowledge of the intervention received by study
participants, since study was retrospective in nature.
Bias in selection of the reported
results
Serious The outcome measurements and analyses were not clearly described. Study reported
outcomes by age subgroups rather than the entire cohort. Study highlighted significant
result in the highest risk age subgroup in the abstract.
Winkelmayer 2011 [22]
Bias due to confounding Moderate Study adjusted for risk factors included in the CHADS2 and HAS-BLED score in the time-fixed
Cox regression analysis, and confirmed using propensity score-adjusted analyses which yielded
similar results.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of
intervention and start of intervention coincide for all subjects (30 days after AF hospital
discharge).
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of
intervention in the regional hospital discharge abstract and drug claims databases.
Bias due to departures from intended
interventions
Low Study used intention-to-treat in which patients were “only censored for end of database”
in the primary analysis. Study also used as-treated analysis which “censored patients at
treatment cross-over”.
Bias due to missing data Low Study obtained data from the national patient registry and regional healthcare claims
database which contains information on relevant ESRD patients. Data were reasonably
complete.
Bias in measurement of outcomes Low Outcomes were identified using previously validated claims-based algorithm. The methods
of outcome assessment were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear
indication of selection of the reported analysis from among multiple analyses or
multiple subgroups.
Olesen 2012 [23]
Bias due to confounding Serious Study adjusted for risk factors included in the CHA2DS2-VASc and HAS-BLED score in the
time-dependent Cox regression analysis, but not confirmed by additional analyses.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start
of intervention and start of intervention coincide for all subjects. “The baseline
assessment and follow-up period began 7 days after discharge.”
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of
intervention in the national patient registry.
Bias due to departures from intended
interventions
Serious Study uses time-dependent analysis, so bias due to departures from intended interventions
is expected. Study did not adjust for switches, co-intervention or problems with
implementation fidelity in the analyses.
Bias due to missing data Low Study obtained data from the national patient registry which contains information on all
residents. Data were reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified using claims-based algorithm. The methods of outcome assessment
were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear
indication of selection of the reported analysis from among multiple analyses or multiple
subgroups.
Khalid 2013 [34]
Bias due to confounding Critical Analyses did not adjust for important confounders such as hypertension, cerebrovascular
disease, diabetes.
Bias in selection of participants into
the study
Critical Participants re-started warfarin after experiencing bleeding outcomes, so their risk profile may
be different. Study included prevalent users, so a potential important amount of follow-up
time is missing for prevalent users from analyses.
Bias in measurement of interventions Moderate Intervention was not well defined. Not clear when the start of intervention was.
Bias due to departures from intended
interventions
Serious Treatment could be discontinued due to experiencing bleeding outcomes. Study did not
address bias due to departures from intended interventions.
Bias due to missing data No
information
Bias in measurement of outcomes Low Intervention not well defined, but were “adjudicated by two blind reviewers”.
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Table 4 Risk of bias assessment of included studies (Continued)
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear
indication of selection of the reported analysis from among multiple analyses or multiple
subgroups.
Wakasugi 2014 [29]
Bias due to confounding Critical For the stroke outcome, analysis was adjusted for CHADS2 score and matched by
propensity score. For the major bleeding and all-cause mortality outcomes, analyses were
not adjusted.
Bias in selection of participants into
the study
Serious All participants who would have been eligible for the target trial were included. Study included
prevalent users, so a potential important amount of follow-up time is missing for prevalent
users from analyses.
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of
intervention since study was conducted prospectively.
Bias due to departures from intended
interventions
Low “The primary analysis was intention-to-treat in which patients who started using warfarin after
study enrollment were not reclassified”, so the specified comparison relates to initiation of
intervention regardless of whether it is continued. To account for possible longitudinal
changes in drug prescription over time, study also repeated the analysis in which patients
were censored when warfarin use changed.
Bias due to missing data No
information
Medical charts of eligible patients treated in a medical center were reviewed. No information
about loss to follow up or missing data.
Bias in measurement of outcomes Low Outcomes were identified from the medical charts. The methods of outcome assessment were
comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
Bonde 2014 [24]
Bias due to confounding Serious Analyses were adjusted for risk factors included in the CHA2DS2-VASc and HAS-BLED score
with age as a continuous covariate. These critically important domains were adjusted for using
Cox regression analysis, but not confirmed by additional analyses.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start
of follow up and start of intervention coincide for all subjects (follow-up began 7 days
after discharge).
Bias in measurement of interventions Moderate Intervention is well defined, but assignment of intervention status by “dividing the number of
tablets dispensed with the estimated daily dosage” was determined retrospectively.
Bias due to departures from intended
interventions
Serious “Treatment is often discontinued in terminal patients” so switches and discontinuation of
treatment were apparent. Such departures from intended intervention may be a result of
outcomes of interest. Study used time-dependent, as-treated Cox regression analysis, but did
not adjust for such departures appropriately.
Bias due to missing data Low Accurate data on all patients actively treated for end-stage CKD with RRT recorded in national
registry, so data were reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified from ICD-8 or ICD-10 codes and the same method of outcome
assessment was applied across intervention groups.
Bias in selection of the reported
results
Serious Study stratified and analyzed results based on CHA2DS2-VASc score subgroups. Main result
reported the high risk subgroup, which appears to be reported on the basis of significant
result.
Carrero 2014 [25]
Bias due to confounding Moderate Study accounted for the most important confounders and confirmed results by propensity
score-matched analysis. Residual confounding is inherent in observational studies.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of
intervention and start of intervention coincide for all subjects (starts with warfarin
prescription at discharge).
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of intervention.
Bias due to departures from intended
interventions
Low “Warfarin use vs no warfarin use was considered as a time-fixed binary variable throughout
the follow-up period.” Specified comparison relates to initiation of intervention regardless of
whether it is continued as in intention-to-treat (ITT) analysis in target trial.
Bias due to missing data Low “The use of unique personal identification number for all Swedish citizens and continuously
updated national registries on death date, cause of death and emigration allow a virtually
complete follow-up” with no loss to follow up.
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Table 4 Risk of bias assessment of included studies (Continued)
Bias in measurement of outcomes Low Outcomes were identified from the National Inpatient Registry and the same method of
outcome assessment was applied across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication of
selection of the reported analysis from among multiple analyses or multiple subgroups.
Chen 2014 [26]
Bias due to confounding Moderate Analyses were adjusted for risk factors for stroke. These critically important domains were
adjusted for using propensity score matched analysis.
Ischemic stroke/TIA history was excluded from the study population. Residual confounding is
inherent in observational studies.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of
intervention and start of intervention coincide for all subjects.
Bias in measurement of interventions Low Intervention status well defined and based on information collected at the time of intervention.
Bias due to departures from intended
interventions
Low The primary analysis was intention-to-treat, thus the specified comparison relates to initiation
of intervention regardless of whether it is continued.
Bias due to missing data Low Variables were identified from the universal national health insurance program, so data were
reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified from the ICD diagnosis codes. The methods of outcome assessment
were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication of
selection of the reported analysis from among multiple analyses or multiple subgroups.
Friberg 2014 [13]
Bias due to confounding Moderate Analyses were adjusted for risk factors for stroke and bleeding. These critically important
domains were adjusted for using propensity score adjusted analysis. Residual confounding
is inherent in observational studies.
Bias in selection of participants into
the study
Serious Study included prevalent users (taking warfarin at baseline i.e. 5 months before, and up to
1 month after the index AF diagnosis), so an important amount of follow-up time is
missing for prevalent users from analyses. Start of follow up and start of intervention do
not coincide for all subjects (time at risk for survival analyses started on Day +14 after
index AF diagnosis).
Bias in measurement of interventions Low Intervention status well defined and based on information collected at the time of intervention.
Bias due to departures from intended
interventions
Low The primary analysis was intention-to-treat, thus the specified comparison relates to initiation of
intervention regardless of whether it is continued.
Bias due to missing data Low Variables were identified from the national patient registry, so data were reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified from the ICD diagnosis codes. The methods of outcome assessment
were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
Shah 2014 [27]
Bias due to confounding Moderate Study adjusted for risk factors included in the CHADS2 and HAS-BLED score in the time-fixed
Cox regression analysis, and confirmed using propensity score-adjusted analyses which yielded
similar results.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of follow
up and start of intervention coincide for all subjects (30 days after AF hospital discharge).
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of
intervention in the regional hospital discharge abstract and drug claims databases.
Bias due to departures from intended
interventions
Low Study uses time-fixed, intention-to-treat analysis, so the specified comparison relates to
initiation of intervention regardless of whether it is continued.
Bias due to missing data Low Study obtained data from the regional hospital and drug claims databases which contains
information on all residents in the region. Data were reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified using claims-based algorithm. The methods of outcome
assessment were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
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Table 4 Risk of bias assessment of included studies (Continued)
Genovesi 2015 [31]
Bias due to confounding Moderate Analyses were adjusted for risk factors for stroke and bleeding. These critically important
domains were adjusted for using multivariate Cox regression analysis followed by
propensity score matched analysis. Residual confounding is inherent in observational
studies.
Bias in selection of participants into
the study
Serious Study included prevalent users (taking anticoagulant at recruitment) and incident users
(starting anticoagulant within 2 weeks following recruitment), so a potential important
amount of follow-up time is missing for prevalent users from analyses.
Bias in measurement of interventions Low Intervention status well defined and based on information collected at the time of intervention.
Bias due to departures from intended
interventions
Low The primary analysis was intention-to-treat, thus the specified comparison relates to initiation
of intervention regardless of whether it is continued.
Bias due to missing data No
information
Patients from 10 hemodialysis center were prospectively followed-up for 2 years. No
information about loss to follow up or missing data.
Bias in measurement of outcomes Low Outcomes were identified from medical charts using clinical diagnosis criteria. The methods
of outcome assessment were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication of
selection of the reported analysis from among multiple analyses or multiple subgroups.
Chan KE 2015 [20]
Bias due to confounding Moderate Study accounted for the most important confounders and “mitigated potential bias from
unmeasured factors by performing a matched analysis which supported the main findings
of the study”. Residual confounding is inherent in observational studies.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of follow
up and start of intervention coincide for all subjects (followed from the time the initiated
anticoagulant treatment de novo).
Bias in measurement of interventions Low Intervention status well defined and based on information collected at the time of intervention.
Bias due to departures from intended
interventions
Serious Patient was censored with discontinuation of treatment medications. Study used Poisson
regression which does not take into account of the potentially varying rate (hazard) ratio for
the effect of intervention.
Bias due to missing data Low “All subjects registered in the database are followed longitudinally, where data parameters are
actively collected,” so data were reasonably complete.
Bias in measurement of outcomes Low The methods of outcome assessment were comparable across intervention groups. Bleeding
outcomes were adjudicated retrospectively, but “the adjudicator was blinded to patient,
treatment group and outcome”.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
Chan PH 2015 [21]
Bias due to confounding Serious Study did not list variables adjusted in the multivariate Cox regression analysis. Results were
not confirmed by additional analyses.
Bias in selection of participants into
the study
Critical Study included patients who had pre-existing AF at enrollment. Study included prevalent
users, so a substantial amount of follow-up time is missing for prevalent users from
analyses. Study excluded patients with incomplete follow-up data, so there may be some
selection bias.
Bias in measurement of interventions Low Intervention is well defined, and based on medical records and discharge summaries at the
time of medication prescription.
Bias due to departures from intended
interventions
Serious Study compared current users vs non-users. Bias due to departure from the intended
intervention is expected, but not adjusted for in the analysis.
Bias due to missing data Low Study data were retrieved from the medical records and discharge summaries from the
territory-wide information network of all public hospitals in the region. Study excluded
patients with incomplete clinical and/or follow-up data, so data were reasonably
complete.
Bias in measurement of outcomes Moderate Outcomes were identified from medical records. The outcome measure may be minimally
influenced by knowledge of the intervention received by study participants, since study was
retrospective in nature.
Bias in selection of the reported
results
Moderate The statistical analyses were not clearly described. There is no clear indication of selection of the
reported analysis from among multiple analyses or multiple subgroups.
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Table 4 Risk of bias assessment of included studies (Continued)
Shen 2015 [28]
Bias due to confounding Moderate Study used Cox regression analysis in the propensity score matched analysis. History of
stroke was not included in the analysis. Unmeasured confounding is inherent in
observational studies.
Bias in selection of participants into
the study
Low All participants who would have been eligible for the target trial were included. Start of
intervention and start of intervention coincide for all subjects (30 days after AF hospital discharge).
Bias in measurement of interventions Low Intervention is well defined, and based solely on information collected at the time of
intervention in the national patient registry.
Bias due to departures from intended
interventions
Low Study used intention-to-treat and as-treated analyses, and adjusted for selection bias using
inverse probability of treatment and censoring-weighted (IPTW) analysis.
Bias due to missing data Low Study obtained data from the national patient registry which contain information on all ESRD
patients. Data were reasonably complete.
Bias in measurement of outcomes Low Outcomes were identified using previously validated claims-based algorithm. The methods of
outcome assessment were comparable across intervention groups.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were clearly defined. There is no clear indication of
selection of the reported analysis from among multiple analyses or multiple subgroups.
Wang 2015 [14]
Bias due to confounding Serious Study reported adjusted multivariate analyses for outcomes (all predictors with P < 0.10 listed).
Confounding inherently not controllable. Results not confirmed by additional analyses.
Bias in selection of participants into
the study
Critical Study included prevalent users, so a substantial amount of follow-up time is missing for
prevalent users from analyses.
Bias in measurement of interventions Low Intervention is well defined, and based on medical records and discharge summaries at the
time of medication prescription.
Bias due to departures from intended
interventions
Serious Study compared current users vs non-users. Bias due to departure from the intended
intervention is expected, but not adjusted for in the analysis.
Bias due to missing data No
information
Study data were retrieved from the medical records in a hospital. No information about loss
to follow up or missing data.
Bias in measurement of outcomes Moderate Outcomes were identified from medical records. The outcome measure may be minimally
influenced by knowledge of the intervention received by study participants, since study was
retrospective in nature.
Bias in selection of the reported
results
Serious Study analyzed multiple outcomes and only reported results for predictors with significant
results (P < 0.10) rather than a priori model. There is a high risk of selective reporting from
among multiple analyses.
Yodogawa 2015 [35]
Bias due to confounding Serious Study adjusted for CHADS2 in Cox regression analysis, but not confirmed by additional
analyses.
Bias in selection of participants into
the study
Critical Study included patients who had pre-existing AF at enrollment. Study included prevalent users,
so a substantial amount of follow-up time is missing for prevalent users from analyses. Study
excluded patients with <6 months life expectancy, so the association may be attenuated since
the high risk patients were excluded from analysis.
Bias in measurement of interventions Moderate Intervention is well defined, but some aspects of the assignments of intervention status were
determined retrospectively since self-reported medication use status may be subject to recall bias.




Study did not describe the analytical method in detail.
Bias due to missing data Low Study was based on a retrospective, observational study on medical records of patients treated in
a hospital. Study excluded patients without follow-up data, so data were reasonably complete.
Bias in measurement of outcomes Moderate Outcomes were identified from medical records. The outcome measure may be minimally
influenced by knowledge of the intervention received by study participants, since study was
retrospective in nature.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were not clearly described. There is no clear indication
of selection of the reported analysis from among multiple analyses or multiple subgroups.
Findlay 2016 [15]
Bias due to confounding Critical Study used Kaplan-Meier survival curve to analyze outcomes between warfarin and no warfarin
group, and did not use adjusted analysis to control for confounding.
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Table 4 Risk of bias assessment of included studies (Continued)
Bias in selection of participants into
the study
Critical Study included patients who had pre-existing AF at enrollment. Study
included prevalent users, so a substantial amount of follow-up time is
missing for prevalent users from analyses.
Bias in measurement of interventions No
information
Study did not provide information about measurement of interventions.
Bias due to departures from intended
interventions
Critical Study did not describe or adjust for any bias due to departures from intended interventions.
Bias due to missing data No
information
Study did not provide information about missing data.
Bias in measurement of outcomes Moderate Outcomes were identified from the electronic patient record, and was reviewed by 2
independent clinicians. The outcome measure may be minimally influenced by knowledge of
the intervention received by study participants, since study was retrospective in nature.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were not clearly described. There is no clear
indication of selection of the reported analysis from among multiple analyses or multiple subgroups.
Tanaka 2016 [16]
Bias due to confounding Critical Study used Kaplan-Meier survival curve to analyze outcomes between warfarin and no warfarin
group, and did not use adjusted analysis to control for confounding.
Bias in selection of participants into
the study
Critical Study included patients who had pre-existing AF at enrollment. Study included prevalent users,
so a substantial amount of follow-up time is missing for prevalent users from analyses.
Bias in measurement of interventions Low Intervention is well defined, and based on records collected during the period of dialysis
initiation. Since study was prospective, assume no recall bias.
Bias due to departures from intended
interventions
Critical Study did not describe or adjust for any bias due to departures from intended interventions.
Bias due to missing data Low Study excluded patients lost to follow-up, so data were reasonably complete.
Bias in measurement of outcomes Moderate Outcomes were identified from survey slips that were sent to the dialysis facilities.
The outcome measure may be minimally influenced by knowledge of the intervention received
by study participants.
Bias in selection of the reported
results
Moderate The outcome measurements and analyses were not clearly described.There is no clear
indication of selection of the reported analysis from among multiple analyses or multiple subgroups.
Tan et al. BMC Nephrology  (2016) 17:157 Page 22 of 26
aNOTE: Weights are from random effects analysis
.
.
D+L Overall  (I-squared = 51.9%, p = 0.052)
Ischemic stroke
D+L Subtotal  (I-squared = 65.0%, p = 0.036)
Chen 2014 [26]
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Fig. 4 a Sensitivity meta-analysis: stroke outcome by warfarin use, excluding studies with prevalent warfarin users. b Sensitivity meta-analysis:
bleeding outcome by warfarin use, excluding studies with prevalent warfarin users. c Sensitivity meta-analysis: mortality by warfarin use, excluding
studies with prevalent warfarin users
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Fig. 5 a Sensitivity meta-analysis of on stroke outcome by warfarin use, excluding studies with critical risk of bias. b Sensitivity meta-analysis of
on bleeding outcome by warfarin use, excluding studies with critical risk of bias. c Sensitivity meta-analysis of on mortality outcome by warfarin
use, excluding studies with critical risk of bias
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